Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: Data from the European cohort of the PREDICTIVE™ study

International Journal of Clinical Practice

Volumn 62, Issue 12, 2008, Pages 1971-1980

  Sreenan, S ^a   Virkamaki A ^b   Zhang, K ^c   Hansen, J B ^c  

^a Royal College of Surgeons in Ireland   (Ireland)

^b Mehilainen Oy   (Finland)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTHRITIS; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC COMA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; TINEA CAPITIS; WEIGHT CHANGE;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 55949103510     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01939.x     Document Type: Article

References (31)

1. Jun HS. Regeneration of pancreatic beta cells. Front Biosci 2008 13 : 6170 82.
2. UK Prospective Diabetes Study (UKPDS) 16. Overview of 6 Years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995 44 : 1249 58.
3. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998 40 (Suppl. S21 5.
4. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 28 : 187 218.
5. Rolla A. The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord 2004 28 (Suppl. 2 S3 7.
6. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007 29 : 1254 70.
7. Brunton S. Insulin regimens for type 2 diabetes mellitus. J Fam Pract 2006 55 : 10S 7S.
8. Salsali A, Nathan M. A review of types 1 and 2 diabetes mellitus and their treatment with insulin. Am J Ther 2006 13 : 349 61.
9. IDF European Diabetes Policy Group. A Desktop Guide to Type 1 (Insulin-dependent) Diabetes. Brussels : International Diabetes Federation, 1998.
10. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels : International Diabetes Federation, 2005.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
12. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
13. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002 287 : 2563 9.
14. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
15. DCCT (The Diabetes Control and Complications Trial Research Group). Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997 46 : 271 86.
16. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003 26 : 590 6.
17. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005 7 : 73 82.
18. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004 27 : 1081 7.
19. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004 26 : 724 36.
20. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004 47 : 622 9.
21. Rašlová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007 27 : 279 85.
22. Kølendorf K, Ross GP, Pavlic-Renar I et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006 23 : 729 35.
23. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007 24 : 27 34.
24. Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a ouble-blind, randomized, crossover study. Diabetes Care 2007 30 : 2447 52.
25. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007 9 : 648 59.
26. Lüddeke HJ, Sreenan S, Aczel S et al. PREDICTIVE - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007 9 : 428 34.
27. Dornhorst A, Lüddeke HJ, Honka M et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008 24 : 369 76.
28. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 49 : 2142 8.
29. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007 23 : 441 54.
30. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005 7 : 56 64.
31. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005 22 : 850 7.